COVID-19: the historicity of therapies in the first year of the Pandemic




SARS-CoV-2; Therapies; Pandemic; COVID-19.


The objective is to know the therapeutic constructs of COVID-19 in its first year of the pandemic. This is a narrative review of the literature, carried out from research in the Biblioteca Virtual de Saúde, Periódicos Capes, PubMed, Cochrane with the standardized descriptors 'Therapy' AND COVID-19, in the first year of the COVID-19 pandemic, after the official declaration of the WHO. As a result, the researched therapeutic targets (in vivo, in vitro, in silico) and published in the first year of this health crisis were described. It was evident that the therapies explored were based on pharmacological and non-pharmacological targets on the host, immune system the virus. The main agents tested in vitro, in vivo, in silico belong to the pharmacological classes of antivirals, antiparasitics, anti-inflammatories, antibiotics as well as monoclonal antibodies, stem cells convalescent plasma. According to the publications, the most cited drugs to treat COVID-19 were hydroxychloroquine, chloroquine, ivermectin, azithromycin, vitamin D, dexamethasone glucocorticoid. It was found that many therapeutic strategies against COVID-19 have been refuted, however, others are being better researched.


Alijotas-Reig, J., Esteve-Valverde, E., Belizna, C., Selva-O’Callaghan, A., Pardos-Gea, J., Quintana, A., Mekinian, A., Anunciacion-Llunell, A., & Miró-Mur, F. (2020). Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmunity Reviews, 19(7), 102569.

Alnababteh, M., Hashmi, M., Drescher, G., Vedantam, K., Kohli, A., Hayat, F., Chopra, R., Oweis, E., & Zaaqoq, A. (2020). Extracorporeal Membrane Oxygenation As Rescue Therapy for COVID-19 Induced Hypoxia: Single-Center Study. Chest, 158(4), A2411.

Andrade, B. S., Rangel, F. de S., Santos, N. O., Freitas, A. dos S., Soares, W. R. de A., Siqueira, S., Barh, D., Góes-Neto, A., Birbrair, A., & Azevedo, V. A. de C. (2020). Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review. Frontiers in Pharmacology, 11(December), 1–12.

Balkhair, A., Al-Zakwani, I., Al Busaidi, M., Al-Khirbash, A., Al Mubaihsi, S., BaTaher, H., Al Aghbari, J., Al Busaidi, I., Al Kindi, M., Baawain, S., Al Alawi, A., Al Lawati, A., Al Rawahi, B., Al-Baimani, K., Al Zidi, K., Elfatih, N., Dawud, B., John, B., Rehman, F., … Balkhair, O. (2021). Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. International Journal of Infectious Diseases, 103, 288–296.

Bassetti, M., Giacobbe, D. R., Aliberti, S., Barisione, E., Centanni, S., De Rosa, F. G., Di Marco, F., Gori, A., Granata, G., Mikulska, M., Petrosillo, N., Richeldi, L., Santus, P., Tascini, C., Vena, A., Viale, P., & Blasi, F. (2020). Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clinical Microbiology and Infection, 26(7), 880–894.

Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., Hajjar, L. A., Pinto, R. C., Balieiro, A. A. S., Pacheco, A. G. F., Santos, J. D. O., Naveca, F. G., Xavier, M. S., Siqueira, A. M., Schwarzbold, A., … Lacerda, M. V. G. (2020). Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Network Open, 3(4), e208857.

Botond, L., László, G., Eniko, G., Alexandra, R., Zsuzsa, V., Éva, N., Eszter, M., Gabriella, B., Ilona, B., Péter, R., János, S., János, S., & István, V. N. (2020). Anti-cytokine therapy in novel coronavirus disease (COVID-19) - The first administration of tocilizumab in Hungary at a department of infectology. Orvosi Hetilap, 161(26), 1070–1077.

Cai, J., Li, H., Zhang, C., Chen, Z., Liu, H., Lei, F., Qin, J. J., Liu, Y. M., Zhou, F., Song, X., Zhou, J., Zhao, Y. C., Wu, B., He, M., Yang, H., Zhu, L., Zhang, P., Ji, Y. X., Zhao, G. N., … Li, H. (2021). The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. Cell Metabolism, 33(2), 258-269.e3.

Campbell, C. M., Guha, A., Haque, T., Neilan, T. G., & Addison, D. (2020). Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review. Journal of Clinical Medicine, 9(9), 2935.

Cantini, F., Niccoli, L., Matarrese, D., Nicastri, E., Stobbione, P., & Goletti, D. (2020). Baricitinib therapy in COVID-19: A pilot study on the safety and clinical impact. Journal of Infection, 81(2), 318–356.

Catteau, L., Dauby, N., Montourcy, M., Bottieau, E., Hautekiet, J., Goetghebeur, E., van Ierssel, S., Duysburgh, E., Van Oyen, H., Wyndham-Thomas, C., Van Beckhoven, D., Bafort, K., Belkhir, L., Bossuyt, N., Caprasse, P., Colombie, V., De Munter, P., Deblonde, J., Delmarcelle, D., … Willems, E. (2020). Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants. International Journal of Antimicrobial Agents, 56(4).

Charan, T. R. V., Pederson, J. M., Saravu, K., Gupta, N., Barrett, A., Davis, A. R., Kallmes, K. M., & Evanson, K. W. (2021). Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. Annals of Medicine and Surgery, 62(December 2020), 43–48.

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223), 507–513.

Choudhary, S., & Silakari, O. (2020). Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19. Virus Research, 289(July), 198146.

Cueto, M. (2020). Os historiadores e as epidemias na América Latina Nas. História, Ciências, Saúde-Manguinhos, 27(4), 11028–11029.

Dassarma, B., Tripathy, S., & Matsabisa, M. (2021). Emergence of ancient convalescent plasma (CP) therapy: To manage COVID-19 pandemic. Transfusion Clinique et Biologique, 28(1), 123–127.

Davoodi, L., Abedi, S. M., Salehifar, E., Alizadeh-Navaei, R., Rouhanizadeh, H., Khorasani, G., & Hosseinimehr, S. J. (2020). Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. International Journal of Clinical Practice, 74(11), 1–8.

de Simone, G., & Mancusi, C. (2020). Finding the right time for anti-inflammatory therapy in COVID-19. International Journal of Infectious Diseases, 101, 247–248.

Dixit, S. (2020). Can moderate-intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19? Medical Hypotheses, 143(April).

Drożdżal, S., Rosik, J., Lechowicz, K., Machaj, F., Kotfis, K., Ghavami, S., & Łos, M. J. (2020). FDA-approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resistance Updates, 53(July), 100719.

Elavarasi, A., Prasad, M., Seth, T., Sahoo, R. K., Madan, K., Nischal, N., Soneja, M., Sharma, A., Maulik, S. K., Shalimar, & Garg, P. (2020). Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. Journal of General Internal Medicine, 35(11), 3308–3314.

Elsawah, H. K., Elsokary, M. A., Elrazzaz, M. G., & Elshafie, A. H. (2021). Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials. Journal of Medical Virology, 93(3), 1265–1275.

Entrenas Castillo, M., Entrenas Costa, L. M., Vaquero Barrios, J. M., Alcalá Díaz, J. F., López Miranda, J., Bouillon, R., & Quesada Gomez, J. M. (2020). “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study.” Journal of Steroid Biochemistry and Molecular Biology, 203(July).

ESSALD. (2020). Ozonoterapia para o tratamento de pacientes adultos com COVID-19. Ara Ii, 1–16.

Feldmann, M., Maini, R. N., Woody, J. N., Holgate, S. T., Winter, G., Rowland, M., Richards, D., & Hussell, T. (2020). Trials of anti-tumor necrosis factor therapy for COVID-19 are urgently needed. The Lancet, 395(10234), 1407–1409.

Ferrando, C., Mellado-Artigas, R., Gea, A., Arruti, E., Aldecoa, C., Adalia, R., Ramasco, F., Monedero, P., Maseda, E., Tamayo, G., Hernández-Sanz, M. L., Mercadal, J., Martín-Grande, A., Kacmarek, R. M., Villar, J., & Suárez-Sipmann, F. (2020). Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: A multicenter, adjusted cohort study. Critical Care, 24(1), 1–11.

Franzini, M., Valdenassi, L., Ricevuti, G., Chirumbolo, S., Depfenhart, M., Bertossi, D., & Tirelli, U. (2020). Oxygen-ozone (O2-O3) immunochemical therapy for patients with COVID-19. Preliminary evidence was reported. International Immunopharmacology, 88(August), 106879.

Garcia, L. P., & Duarte, E. (2020). Intervenções não farmacológicas para o enfrentamento à epidemia da COVID-19 no Brasil. Epidemiologia e Servicos de Saude : Revista Do Sistema Unico de Saude Do Brasil, 29(2), 1–4.

Gendelman, O., Amital, H., Luigi, N., & Watad, A. (2020). Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmunity Reviews Journal, 19(January), 1–4.

Gollob, M. H. (2020). COVID-19, Clinical Trials, and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm. Journal of the American College of Cardiology, 75(25), 3184–3186.

González-Gay, M. A., Castañeda, S., & Ancochea, J. (2021). Biologic Therapy in COVID-19. Archivos de Bronconeumologia, 57(1), 1–2.

Hamizi, K., Aouidane, S., & Belaaloui, G. (2020). Etoposide-based therapy for severe forms of COVID-19. Medical Hypotheses, 142(April), 109826.

Hariyanto, T. I., & Kurniawan, A. (2020). Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(6), 1613–1615.

Homolak, J., & Kodvanj, I. (2020). Widely available lysosome targeting agents should be considered a potential therapy for COVID-19. International Journal of Antimicrobial Agents, 56(2), 106044.

Huang, R., Zhu, C., Jian Wang, Xue, L., Li, C., Yan, X., Huang, S., Zhang, B., Zhu, L., Xu, T., Ming, F., Zhao, Y., Cheng, J., Shao, H., Zhao, X. an, Sang, D., Zhao, H., Guan, X., Chen, X., … Wu, C. (2020). Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients. European Journal of Pharmacology, 889(July), 173556.

Ip, A., Berry, D. A., Hansen, E., Goy, A. H., Pecora, A. L., Sinclaire, B. A., Bednarz, U., Marafelias, M., Berry, S. M., Berry, N. S., Mathura, S., Sawczuk, I. S., Biran, N., Go, R. C., Sperber, S., Piwoz, J. A., Balani, B., Cicogna, C., Sebti, R., … Goldberg, S. L. (2020). Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. PLoS ONE, 15(8 August), 1–19.

Izadi, M., Cegolon, L., Javanbakht, M., & Sarafzadeh, A. (2020). Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review. International Immunopharmacology, 92(January).

Jankowska, E. A., Sierpiński, R., Tkaczyszyn, M., Drozd, M., Szachniewicz, J., Duda-Sikuła, M., Knysz, B., Simon, K., Szenborn, L., & Ponikowski, P. (2020). Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns. Kardiologia Polska, 78(7–8), 811–817.

Jha, A. K., Kumar, R., Goenka, M. K., & Dayal, V. M. (2020). Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update. Journal of Digestive Endoscopy, 11(01), 69–72.

Ji, F., Liu, W., Hao, D. A., Cheng, J., Tong, X. C., Hao, J. G., Wang, L. P., Li, C. Y., Dai, M. J., & Yan, X. B. (2021). Use of convalescent plasma therapy in eight individuals with mild COVID-19. New Microbes and New Infections, 39, 100814.

Kirsch, D. G. (2020). Radiation Therapy as a Treatment for COVID-19? International Journal of Radiation Oncology Biology Physics, 108(5), 1140–1142.

Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J. C., Badie, J., Royer, P. Y., Toko, L., Mezher, C., Kadiane-Oussou, N. J., Bossert, M., Bozgan, A. M., Charpentier, A., Roux, M. F., Contreras, R., Mazurier, I., Dussert, P., Gendrin, V., & Conrozier, T. (2020). Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Medecine et Maladies Infectieuses, 50(5), 397–400.

Lana, R. M., Coelho, F. C., Da Costa Gomes, M. F., Cruz, O. G., Bastos, L. S., Villela, D. A. M., & Codeço, C. T. (2020). The novel coronavirus (SARS-CoV-2) emergency and the role of timely and effective national health surveillance. Cadernos de Saude Publica, 36(3).

Langhi, D. M., Santis, G. C. De, & Bordin, J. O. (2020). COVID-19 convalescent plasma transfusion. Hematology, Transfusion and Cell Therapy, 42(2), 113–115.

Laurence, J., Mulvey, J. J., Seshadri, M., Racanelli, A., Harp, J., Schenck, E. J., Zappetti, D., Horn, E. M., & Magro, C. M. (2020). Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clinical Immunology, 219(July), 108555.

Lawlor, M., Gupta, A., Ranard, L. S., Madhavan, M. V., Li, J., Eisenberger, A., Parikh, S. A., Sethi, S. S., & Masoumi, A. (2021). Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy. Thrombosis Research, 198(June 2020), 79–82.

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., … Feng, Z. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine, 382(13), 1199–1207.

Li, S., Liu, C., Guo, F., Taleb, S. J., Tong, M., & Shang, D. (2020). Traditional Chinese medicine a potential therapy for COVID-19. American Journal of Chinese Medicine, 48(6), 1263–1277.

Li, X., Yang, Y., Liu, L., Yang, X., Zhao, X., Li, Y., Ge, Y., Shi, Y., Lv, P., Zhang, J., Bai, T., Zhou, H., Luo, P., & Huang, S. (2020). Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019. Pharmacological Research, 160, 105036.

Li, Y., Shi, K., Qi, F., Yu, Z., Chen, C., Pan, J., Wu, G., Chen, Y., Li, J., Chen, Y., Zhou, T., Li, X., & Xia, J. (2021). Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study. International Journal of Infectious Diseases, 103, 507–513.

Lim, Z. J., Subramaniam, A., Reddy, M. P., Blecher, G., Kadam, U., Afroz, A., Billah, B., Ashwin, S., Kubicki, M., Bilotta, F., Curtis, J. R., & Rubulotta, F. (2021). Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. American Journal of Respiratory and Critical Care Medicine, 203(1), 54–66.

Liu, W., Zhu, H. L., & Duan, Y. (2020). Virus-, host-, immune-based targets for COVID-19 therapy. Drug Discovery Today, 25(12), 2071–2073.

Liu, X., Long, C., Xiong, Q., Chen, C., Ma, J., Su, Y., & Hong, K. (2020). Association of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. Clinical Cardiology, July, 1–10.

López-Alcalde, J., Yan, Y., Witt, C. M., & Barth, J. (2020). The current State of Research about Chinese Herbal Medicines (CHM) for the Treatment of Coronavirus Disease 2019 (COVID-19): A Scoping Review. Journal of Alternative and Complementary Medicine, 26(7), 557–570.

Lovetrue, B. (2020). The AI-discovered etiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients. Medical Hypotheses, 144(August), 110180.

Mansourabadi, A. H., Sadeghalvad, M., Mohammadi-Motlagh, H. R., & Rezaei, N. (2020). The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19. Life Sciences, 258(June), 118185.

Mattos-Silva, P., Felix, N. S., Silva, P. L., Robba, C., Battaglini, D., Pelosi, P., Rocco, P. R. M., & Cruz, F. F. (2020). Pros and cons of corticosteroid therapy for COVID-19 patients. Respiratory Physiology and Neurobiology, 280(June), 103492.

Muchtaridi, M., Fauzi, M., Ikram, N. K. K., Gazzali, A. M., & Wahab, H. A. (2020). Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. Molecules, 25(17).

Nadaroglu, H. (2020). Antiviral drugs and plasma therapy used for COVID-19 treatment: a nationwide Turkish algorithm. Drug Metabolism Reviews, 52(4), 531–539.

Nagoba, B., Gavkare, A., Jamadar, N., Mumbre, S., & Selkar, S. (2020). Positive aspects, negative aspects, and limitations of plasma therapy with special reference to COVID-19. Journal of Infection and Public Health, 13(12), 1818–1822.

Najar Nobari, N., Seirafianpour, F., Mashayekhi, F., & Goodarzi, A. (2020). A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. Dermatologic Therapy, October 2020, 1–16.

Nasonov, E., & Samsonov, M. (2020). The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomedicine and Pharmacotherapy, 131, 110698.

Oladele, J. O., Ajayi, E. I., Oyeleke, O. M., Oladele, O. T., Olowookere, B. D., Adeniyi, B. M., Oyewole, O. I., & Oladiji, A. T. (2020). A systematic review on COVID-19 pandemic with special emphasis on curative potentials of Nigeria-based medicinal plants. Heliyon, 6(9), e04897.

OMS. (2020). Therapeutics and COVID-19. Living Guideline, November, 58.

Parasher, A. (2020). COVID-19: Current understanding of its pathophysiology, clinical presentation, and treatment. Postgraduate Medical Journal, 1(1), 1–9.

Patel, M., Gangemi, A., Marron, R., Chowdhury, J., Yousef, I., Zheng, M., Mills, N., Tragesser, L., Giurintano, J., Gupta, R., Gordon, M., Rali, P., D’Alonso, G., Fleece, D., Zhao, H., Patlakh, N., & Criner, G. (2020). Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure. BMJ Open Respiratory Research, 7(1), 1–11.

Poor, H. D., Ventetuolo, C. E., Tolbert, T., Chun, G., Serrao, G., Zeidman, A., Dangayach, N. S., Olin, J., Kohli‐Seth, R., & Powell, C. A. (2020). COVID‐19 critical illness pathophysiology drove by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clinical and Translational Medicine, 10(2), 3–7.

Procter, B. C., Ross, C., Pickard, V., Smith, E., Hanson, C., & McCullough, P. A. (2021). Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine, 21(4), 611–614.

Rafiee, F., Keshavarz, P., Katal, S., Assadi, M., Nejati, S. F., Ebrahimian Sadabad, F., & Gholamrezanezhad, A. (2021). Coronavirus Disease 2019 (COVID-19) in Molecular Imaging: A Systematic Review of Incidental Detection of SARS-CoV-2 Pneumonia on PET Studies. Seminars in Nuclear Medicine, 51(2), 178–191.

Razmi, M., Hashemi, F., Gheytanchi, E., Dehghan Manshadi, M., Ghods, R., & Madjd, Z. (2020). Immunomodulatory-based therapy as potentially promising treatment strategy against severe COVID-19 patients: A systematic review. International Immunopharmacology, 88(June), 106942.

Rodríguez-Molinero, A., Pérez-López, C., Gálvez-Barrón, C., Miñarro, A., Rodríguez Gullello, E. A., Collado Pérez, I., Milà Ràfols, N., Mónaco, E. E., Hidalgo García, A., Añaños Carrasco, G., & Chamero Pastilla, A. (2021). Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study. Medicina Clinica, 156(1), 7–12.

Russo, V., Di Maio, M., Attena, E., Silverio, A., Scudiero, F., Celentani, D., Lodigiani, C., & Di Micco, P. (2020). Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacological Research, 159, 104965.

Saeedi Saravi, S. S., & Beer, J. H. (2020). Apelin-potential therapy for COVID-19? Journal of Molecular and Cellular Cardiology, 145(June), 84–87.

Samaddar, A., Grover, M., & Nag, V. L. (2020). Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. Frontiers in Pharmacology, 11(585888), 1–23.

Sauñe, P. M., Bryce-Alberti, M., Portmann-Baracco, A. S., & Accinelli, R. A. (2020). Methylprednisolone pulse therapy: An alternative management of severe COVID-19. Respiratory Medicine Case Reports, 31(June), 12–14.

Seyedpour, S., Khodaei, B., Loghman, A. H., Seyedpour, N., Kisomi, M. F., Balibegloo, M., Nezamabadi, S. S., Gholami, B., Saghazadeh, A., & Rezaei, N. (2020). Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies. Journal of Cellular Physiology, June.

Seyhan, A. U., Doganay, F., Yilmaz, E., Topal, N. P., & Ak, R. (2020). Investigation of QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID‐19. Journal of the College of Physicians and Surgeons Pakistan, 30(10), S153–S157.

Shah, M., Captain, J., Vaidya, V., Kulkarni, A., Valsangkar, K., Nair, P. M. K., & Ganu, G. (2021). Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study). International Immunopharmacology, 91(October 2020), 107301.

Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, 24, 91–98.

Shi, C., Tingting, W., Li, J. P., Sullivan, M. A., Wang, C., Wang, H., Deng, B., & Zhang, Y. (2021). Comprehensive Landscape of Heparin Therapy for COVID-19. Carbohydrate Polymers, 254(August), 117232.

Stremmel, C., Kellnar, A., Massberg, S., & Kääb, S. (2020). Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia. Journal of Cardiovascular Pharmacology and Therapeutics, 25(6), 497–502.

Sun, M., Xu, Y., He, H., Zhang, L., Wang, X., Qiu, Q., Sun, C., Guo, Y., Qiu, S., & Ma, K. (2020). A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. International Journal of Infectious Diseases, 98, 334–346.

Taha, M., Sharma, A., & Soubani, A. (2020). Clinical deterioration during neutropenia recovery after G-CSF therapy inpatient with COVID-19. Respiratory Medicine Case Reports, 31, 101231.

Takahashi, W., Yoneda, T., Koba, H., Ueda, T., Tsuji, N., Ogawa, H., & Asakura, H. (2021). Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. International Journal of Infectious Diseases, 102, 529–531.

Tong, S., Su, Y., Yu, Y., Wu, C., Chen, J., Wang, S., & Jiang, J. (2020). Ribavirin therapy for severe COVID-19: a retrospective cohort study. International Journal of Antimicrobial Agents, 56(3), 1–5.

Trivedi, N., Verma, A., & Kumar, D. (2020). Possible treatment and strategies for COVID-19: review and assessment. European Review for Medical and Pharmacological Sciences, 24(23), 12593–12608.

Valizadeh, H., Abdolmohammadi-vahid, S., Danshina, S., Ziya Gencer, M., Ammari, A., Sadeghi, A., Roshangar, L., Aslani, S., Esmaeilzadeh, A., Ghaebi, M., Valizadeh, S., & Ahmadi, M. (2020). Nano-curcumin therapy is a promising method in modulating inflammatory cytokines in COVID-19 patients. International Immunopharmacology, 89(June), 107088.

Veenstra, J., Buechler, C. R., Robinson, G., Chapman, S., Adelman, M., Tisack, A., Dimitrion, P., Todter, E., Kohen, L., & Lim, H. W. (2020). Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak. Journal of the American Academy of Dermatology, 83(6), 1696–1703.

Vegivinti, C. T. R., Pederson, J. M., Saravu, K., Gupta, N., Evanson, K. W., Kamrowski, S., Schmidt, M., Barrett, A., Trent, H., Dibas, M., Reierson, N. L., Mikoff, N., Pisipati, S., Joseph, B. A., Selvan, P. T., Dmytriw, A. A., Pulakurthi, Y. S., Keesari, P. R., Sriram, V., … Hassan, A. E. (2021). Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis. Journal of Clinical Apheresis, November 2020, 1–13.

Vianello, A., Arcaro, G., Molena, B., Turato, C., Sukthi, A., Guarnieri, G., Lugato, F., Senna, G., & Navalesi, P. (2020). High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. Thorax, 75(11), 998–1000.

Wang, N., Zhan, Y., Zhu, L., Hou, Z., Liu, F., Song, P., Qiu, F., Wang, X., Zou, X., Wan, D., Qian, X., Wang, S., Guo, Y., Yu, H., Cui, M., Tong, G., Xu, Y., Zheng, Z., Lu, Y., & Hong, P. (2020). Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host and Microbe, 28(3), 455-464.e2.

Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., Prescott, H. C., & Joost Wiersinga, W. (2020). Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) AReview. JAMA, 324(8), 782–793.

Xu, P., Huang, J., Fan, Z., Huang, W., Qi, M., Lin, X., Song, W., & Yi, L. (2020). Arbidol/IFN-α2b therapy for patients with coronavirus disease 2019: a retrospective multicenter cohort study. Microbes and Infection, 22(4–5), 200–205.

Yao, T. T., Qian, J. D., Zhu, W. Y., Wang, Y., & Wang, G. Q. (2020). A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease-19 treatment option. Journal of Medical Virology, 92(6), 556–563.

Yousefifard, M., Zali, A., Mohamed Ali, K., Madani Neishaboori, A., Zarghi, A., Hosseini, M., Safari, S., Ali, M. K., & Neishaboori, M. A. (2020). Antiviral Therapy in Management ofCOVID-19: a Systematic Review on Current Evidence. Archives of Academic Emergency Medicine, 8(1), 45.

Zhao, M. (2020). Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. International Journal of Antimicrobial Agents, 55(6), 105982.

Zhaori, G., Lu, L., Liu, C., & Guo, Y. (2020). Progresses in clinical studies on antiviral therapies for COVID-19—Experience and lessons in the design of clinical trials. Pediatric Investigation, 4(4), 263–274.



How to Cite

ANDOLFATTO, D.; ZANATTA, L.; FERRAZ, L. COVID-19: the historicity of therapies in the first year of the Pandemic. Research, Society and Development, [S. l.], v. 11, n. 2, p. e60011226307, 2022. DOI: 10.33448/rsd-v11i2.26307. Disponível em: Acesso em: 21 jul. 2024.



Health Sciences